PiVily Quarterly Report · Interim update
Reporting standards and the work of communicating safety
An interim Q4 review through 23 October 2026: FDA reporting standards, UK safety communication, EU assessment activity, and upcoming data and AI discussions. A Nigerian guidance document adds regional context.
The quarter in one reading
The early-quarter record puts attention on implementation and understanding: the format in which safety information is submitted, the way risks are explained, and the evidence people need to interpret them.
This interim edition reviews selected official materials available through 23 October 2026. It includes newly applicable requirements, recent publications, and clearly identified background context. Q4 remains in progress; this is not a full-quarter assessment.
Material signals
What moved—and why it mattered.
FDA’s E2B(R3) transition date has passed.
FDA’s electronic-submissions page states that, from 1 October 2026, postmarketing ICSRs for human drugs, biologics, and drug- or biologic-led combination products submitted through ESG NextGen must use E2B(R3). The same page describes acceptance of E2D(R1)-aligned study-type values for patient support programmes, market research, and organised collection from digital platforms.
FDA: AEMS electronic submissions: E2B(R3) timelines and E2D(R1) alignment
A submission-format milestone also creates a useful checkpoint for how source information, classifications, and transmission records fit together. A shared technical standard does not by itself establish consistent interpretation.
Can the organisation explain how its source classifications and transmitted data relate to the applicable FDA reporting standard?
MHRA’s antidepressant measures focus on how established risks are understood.
On 15 October, MHRA described strengthened antidepressant risk communications, including a boxed patient-leaflet warning and a patient card. A supporting safety leaflet is planned for 2027. The measures follow a review involving patients and families; MHRA distinguishes these communication changes from newly identified risks.
MHRA: Antidepressants: new measures to improve risk communication, 15 October 2026
Communication is a substantive part of safety work. The example invites attention to wording, format, timing, and the experience of people who need to understand the information.
How does a team assess whether a safety message is understood, rather than only confirming that it was distributed?
PRAC’s early-October record shows the breadth of ongoing assessment.
For its 28 September–1 October meeting, EMA’s PRAC highlights reported nine safety signals, 85 PSUR single assessments, 49 risk management plans, and 16 post-authorisation safety studies. The page states that these monthly figures are based on the draft agenda.
These counts describe different types of committee activity; they are not a measure of patient harm or a comparison of product risk. Their practical value here is to show the range of evidence streams that PV professionals need to understand.
Can colleagues explain how signal assessment, periodic review, risk management, and post-authorisation studies contribute different information?
EMA’s latest data newsletter connects accessibility with scientific discussion.
EMA’s latest Big Data Highlights bulletin reports routine publication of visual abstracts for finalised DARWIN EU studies. It also lists an HMA–EMA AI and data forum for 12–13 November and an EudraVigilance and signal-detection forum for 1 December 2026. Both events are future activities as of this review.
HMA / EMA: Big Data Highlights: latest bulletin reviewed 23 October 2026
Accessible summaries and professional discussion can help more people engage with evidence. The underlying study and its limitations remain essential to interpretation. Announced events indicate topics for discussion, not completed decisions or new requirements.
What information does a reader need alongside a visual summary to understand the study’s relevance and limitations?
NAFDAC’s safety-communication guidance provides a local perspective.
NAFDAC’s GVP Chapter 4 on safety communication carries an effective date of 16 July 2026. It describes audience-appropriate communication, oversight of digital channels, and evaluation of whether messages are received, understood, and acted on. It is included as existing regional context, not as a newly effective October measure.
NAFDAC: GVP Chapter 4: Safety Communication, effective 16 July 2026
Comparing public guidance across jurisdictions can sharpen educational discussion about shared principles and local responsibilities. It should preserve the distinctions between each authority’s documents and implementation context.
When discussing global communication principles, which local sources and practitioner perspectives should inform the conversation?
Forward watch
Questions to carry forward.
- Review the published outcomes of the November AI and data forum and December EudraVigilance forum when available; their occurrence and conclusions are not assumed here.
- MHRA lists MedSafetyWeek for 2–8 November 2026. Follow the official campaign materials and distinguish awareness activity from evidence that reporting behaviour has changed.
- Continue checking official reporting, guidance, and safety-communication pages as the quarter develops. This selective interim report is not a complete global regulatory tracker.
Method & source register
Trace the reading back to the record.
PiVily selects developments for system-level relevance to human pharmacovigilance. Facts are attributed to official publishers; interpretation is editorial. This is not an exhaustive jurisdictional change log or organisation-specific advice.
- FDAAEMS electronic submissions: E2B(R3) timelines and E2D(R1) alignment
- MHRAAntidepressants: new measures to improve risk communication, 15 October 2026
- EMAPRAC meeting highlights: 28 September–1 October 2026
- HMA / EMABig Data Highlights: latest bulletin reviewed 23 October 2026
- NAFDACGVP Chapter 4: Safety Communication, effective 16 July 2026
- MHRAYellow Card: MedSafetyWeek, 2–8 November 2026